{
    "clinical_study": {
        "@rank": "21574", 
        "arm_group": {
            "arm_group_label": "Ublituximab + Lenalidomide", 
            "arm_group_type": "Experimental", 
            "description": "4 cohorts, with 3 - 6 patients per cohort, as follows:\nCohort 1:  Ublituximab 450 mg + Lenalidomide 10 mg\nCohort 2:  Ublituximab 450 mg + Lenalidomide 15 mg\nCohort 3:  Ublituximab 600 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1)\nCohort 4:  Ublituximab 900 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1)\nUblituximab is an IV infusion on days 1, 8, and 15 of cycles 1 & 2 followed by a planned maintenance with a single infusion on day 1 of cycles 3 thru 6.\nLenalidomide is taken orally on days 9 - 28 of cycle 1 followed by daily administration on Days 1 - 28 for cycles 2 thru 6. Non-hodgkins lymphoma patients may have up to a 7 day rest period (Days 21-28) in any cycle."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether ublituximab in combination with\n      lenalidomide (Revlimid\u00ae) is safe and effective in patients with B-Cell Lymphoid Malignancies\n      who have relapsed or are refractory after CD20 directed antibody therapy"
        }, 
        "brief_title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-Hodgkins Lymphoma", 
            "Chronic Lymphocytic Leukemia", 
            "Small Lymphocytic Lymphoma", 
            "B-cell Lymphomas", 
            "Marginal Zone Lymphoma", 
            "Mantle Cell Lymphoma", 
            "Waldenstrom's Macroglobulinemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Waldenstrom Macroglobulinemia", 
                "Lymphoma, B-Cell", 
                "Lymphoma, B-Cell, Marginal Zone", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Relapsed or refractory B-cell non-Hodgkins Lymphoma (NHL), Chronic Lymphocytic\n             Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)\n\n          -  Patients must have received at least one prior line of therapy with an anti-CD20\n             antibody (i.e. rituximab, ofatumumab, etc.) or an anti-CD20 antibody containing\n             regimen\n\n          -  Measurable or evaluable Disease\n\n          -  Eastern Cooperative Oncology Group performance status 0, 1 or 2\n\n          -  Patients ineligible for high dose or combination chemotherapy + stem cell transplant\n\n          -  No active or chronic infection of Hepatitis B or C and no history of HIV based on\n             negative serology\n\n          -  All study participants must be registered into the mandatory RevAssist\u00ae program, and\n             be willing and able to comply with the requirements of RevAssist\u00ae\n\n        Exclusion Criteria:\n\n          -  Prior chemotherapy, investigational therapy or radiotherapy within 3 weeks of study\n             entry\n\n          -  Prior autologous or allogeneic stem cell transplantation within 6 months of study\n             entry\n\n          -  History of severe hypersensitivity or anaphylaxis to prior murine or mouse/human\n             chimeric antibodies, or to any component of ublituximab, or with prior lenalidomide\n             or thalidomide\n\n          -  Uncontrolled inter-current illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness that would limit compliance with study\n             requirements\n\n          -  History of deep vein thrombosis (DVT) or pulmonary embolus (PE) in the six months\n             prior to Day 1 of Cycle 1\n\n          -  Pregnant women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744912", 
            "org_study_id": "TGTX 1101-102"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ublituximab + Lenalidomide", 
                "description": "Ublituximab is a novel monoclonal antibody targeting CD20", 
                "intervention_name": "Ublituximab", 
                "intervention_type": "Drug", 
                "other_name": "TG-1101"
            }, 
            {
                "arm_group_label": "Ublituximab + Lenalidomide", 
                "description": "Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects", 
                "intervention_name": "Lenalidomide", 
                "intervention_type": "Drug", 
                "other_name": "Revlimid"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal", 
                "Thalidomide", 
                "Lenalidomide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Lymphoma", 
            "monoclonal antibody", 
            "immunomodulatory agent", 
            "ublituximab", 
            "lenalidomide"
        ], 
        "lastchanged_date": "January 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Huntsville", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35805"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lawrenceville", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30046"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20817"
                    }, 
                    "name": "TG Therapeutics Investigational Trial Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid\u00ae) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy", 
        "other_outcome": {
            "measure": "Pharmacokinetic profile including Peak Plasma Concentration (Cmax)", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 months"
        }, 
        "overall_official": {
            "affiliation": "TG Therapeutics, Inc.", 
            "last_name": "TG Therapeutics Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Maximum Tolerated Dose will be determined by a Data Safety Monitoring Board", 
            "measure": "Maximum Tolerated Dose acceptable for participants", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744912"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Efficacy will include overall response rate and duration of response", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "After 8 weeks and then every 12 weeks"
        }, 
        "source": "TG Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TG Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}